Business Context and Reporting Period
This Form 6-K filing by Compugen Ltd. covers the month of November 2006. The registrant is a foreign private issuer based in Tel-Aviv, Israel, focused on the discovery and licensing of product candidates for the drug and diagnostic industries. The company utilizes computational biology to identify therapeutics and biomarkers, primarily targeting cancer, immune-related, and cardiovascular diseases.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report serves solely to disclose a corporate event and does not contain financial statements or quantitative performance data.
Material Changes
No material financial changes versus a prior comparable period are reported in this document. The filing is informational regarding a scheduled corporate presentation.
Guidance, Outlook, and Management Commentary
- Upcoming Event: Martin Gerstel, Chairman of the Board, is scheduled to present at the Rodman & Renshaw Techvest 8th Annual Healthcare Conference.
- Date and Time: Wednesday, November 8, 2006, at 09:55 AM (Eastern Time).
- Location: New York Palace Hotel, New York City.
- Access: A live webcast and a 90-day replay will be available via the company website and the conference provider.
- Business Strategy: The company continues to pursue commercialization through milestone and revenue-sharing out-licensing and joint development agreements. It maintains affiliates in agricultural biotechnology (Evogene) and small-molecule drug discovery (Keddem Bioscience).
Key Facts for Investor Verification
- Verify the date and time of the Chairman's presentation at the Rodman & Renshaw conference (November 8, 2006).
- Confirm the availability of the webcast replay on the company website or the conference portal.
- Note that this filing contains no financial results; investors should refer to the most recent Form 20-F for financial data.
- Review the company's pipeline status regarding cancer, immune-related, and cardiovascular disease candidates as discussed in the upcoming presentation.